Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-07-07

Clinical Trial Update: A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing therapeutic equivalence of Fluticasone Propionate/Salmeterol inhalation powder to Advair Diskus in asthma patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Advair Diskus 100/50 mcg Inhalation Powder (Fluticasone Propionate/Salmeterol)
  • Fluticasone Propionate 100 mcg / Salmeterol 50 mcg Inhalation Powder

Snippet

Sponsor: Respirent Pharmaceuticals Co Ltd. | Conditions: Asthma | Phase 3 | Status: COMPLETED